Valuation: Makers Laboratories Limited

Market Cap 90Cr 93.91L 81.61L 76.2L 69.95L 1.32Cr 1.34Cr 8.98Cr 3.52Cr 45Cr 3.53Cr 3.45Cr 147.23Cr P/E 2025
10.2x
P/E 2026 33.9x
Enterprise Value 84Cr 87.98L 76.46L 71.39L 65.53L 1.24Cr 1.26Cr 8.42Cr 3.3Cr 42Cr 3.3Cr 3.23Cr 137.93Cr EV / Sales 2025
0.67x
EV / Sales 2026 0.53x
Free-Float
31.45%
Yield 2025 *
-
Yield 2026 -
26/05 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
10/02 Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
07/11 Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
29/25/29 CARE Affirms BBB+ Rating on Makers Laboratories' Long-Term Bank Financing; Outlook Stable MT
08/25/08 Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
08/25/08 Makers Laboratories Returns to Consolidated Profit in Fiscal Q1; Shares Slide MT
26/25/26 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
29/24/29 Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
06/24/06 Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
23/24/23 Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories MT
23/24/23 Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
23/24/23 Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
15/24/15 Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024 CI
1 day+1.78%
1 week+1.34%
Current month+1.78%
1 month-5.81%
3 months+7.55%
6 months+30.05%
Current year+28.40%
1 week 146.2
Extreme 146.2
156.5
1 month 145
Extreme 145
164.95
Current year 112.1
Extreme 112.1
186.7
1 year 109
Extreme 109
186.7
3 years 98.05
Extreme 98.05
230
5 years 94
Extreme 94
238
10 years 23.2
Extreme 23.2
344.8
Manager TitleAgeSince
Chief Executive Officer 51 11/08/2011
Director of Finance/CFO 59 30/10/2017
Compliance Officer - 23/05/2024
Director TitleAgeSince
Director/Board Member 51 11/08/2011
Director/Board Member 52 29/01/2018
Chairman 77 28/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%+1.34%-2.29%+34.19% 92.13L
-1.36%+1.15%+20.48%+72.96% 5TCr
+3.60%+3.09%+54.20%+116.82% 3.66TCr
+0.08%+4.52%-1.89%+26.20% 1.25TCr
-0.51%+1.11%+18.12%+78.33% 1.18TCr
+2.41%-0.76%+30.73%+130.67% 903.81Cr
-1.95%-4.00%+42.44%-12.71% 702.99Cr
+1.10%+1.62%+15.04%+33.59% 679.37Cr
-0.17%+1.73%+7.84%+185.66% 660.39Cr
-0.24%+3.14%-35.41%+8.71% 549.26Cr
Average +0.47%+0.94%+14.93%+67.44% 1.46TCr
Weighted average by Cap. +0.49%+1.31%+25.60%+80.70%

Financials

2025 2026
Net sales 120.75Cr 1.27Cr 1.1Cr 1.03Cr 94.37L 1.78Cr 1.81Cr 12Cr 4.75Cr 60Cr 4.76Cr 4.65Cr 198.62Cr 140.87Cr 1.48Cr 1.28Cr 1.2Cr 1.1Cr 2.08Cr 2.11Cr 14Cr 5.54Cr 70Cr 5.55Cr 5.43Cr 231.71Cr
Net income 7.49Cr 8L 7L 6L 6L 11.04L 11.23L 75.19L 29.45L 3.74Cr 29.52L 28.87L 12Cr 2.35Cr 2L 2L 2L 2L 3L 4L 23.6L 9L 1.17Cr 9L 9L 3.87Cr
Net Debt 4.82Cr 5L 4L 4L 4L 7L 7L 48.37L 18.95L 2.4Cr 18.99L 18.57L 7.93Cr -5.65Cr -6L -5L -5L -4L -8L -8L -56.71L -22.21L -2.82Cr -22.26L -21.77L -9.29Cr
Logo Makers Laboratories Limited
Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company's segments include Pharmaceutical and Chemical Manufacturing. It has one manufacturing unit in India manufacturing formulations for the Indian market. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimesulide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). It also offers a range of diabetic and hypertensive drugs, including Voglibose, Gli-me range (Glimepiride + Metformin +Pioglitazone), and Hypernorm range (Telmisartan). Its product categories include Inspira - Retail Packs and Experia - Bulk Packs. Its Inspira - Retail Packs include anthelmintics, anti-biotics, anti-emetics and anti-nauseants. Its Experia - Bulk Packs include betamethasone 0.5 mg tablets, chloramphenicol capsules 250 mg and diclofenac 50 mg tablets.
Employees
114
Date Price Change Volume
03/26/03 151.70 +1.78% 1,287
31/26/31 ₹149.05 -1.62% 170
30/26/30 ₹151.50 -0.53% 3,343
29/26/29 ₹152.30 -1.65% 1,773
28/26/28 ₹154.85 +2.08% 1,404
  1. Stock Market
  2. Stocks
  3. MAKERSL6 Stock